Panbela Therapeutics (PBLA) 10-K 16 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 13, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001029125
Entity Registrant Name	Panbela Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-39468
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2805017
Entity Address, Address Line One	712 Vista Blvd, #305
Entity Address, City or Town	Waconia
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55387
City Area Code	952
Local Phone Number	479-1196
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	PBLA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 11,425,882
Entity Common Stock, Shares Outstanding		14,595,873
Auditor Firm ID	677
Auditor Name	Cherry Bekaert
Auditor Location	Tampa, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,285,000	$ 11,867,000
Prepaid expenses and other current assets	443,000	91,000
Income tax receivable	49,000	321,000
Total current assets	1,777,000	12,279,000
Other noncurrent assets	3,201,000	593,000
Total assets	4,978,000	12,872,000
Current liabilities:
Accounts payable	2,865,000	640,000
Accrued expenses	2,993,000	2,020,000
Accrued interest payable	325,000	0
Note payable	650,000	0
Debt, current portion	1,000,000	0
Total current liabilities	7,833,000	2,660,000
Debt, net of current portion	5,194,000	0
Total non current liabilities	5,194,000	0
Total liabilities	13,027,000	2,660,000
Stockholders' (deficit) equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of December 31, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 1,049,644 and 335,961 shares issued and outstanding, as of December 31, 2022 and December 31, 2021, respectively	1,000	0
Additional paid-in capital	82,285,000	66,240,000
Accumulated deficit	(91,094,000)	(56,161,000)
Accumulated comprehensive income	759,000	133,000
Total stockholders' (deficit) equity	(8,049,000)	10,212,000
Total liabilities and stockholders' (deficit) equity	$ 4,978,000	$ 12,872,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	1,049,644	335,961
Common stock, shares outstanding (in shares)	1,049,644	335,961

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
General and administrative	$ 6,044	$ 4,587
Research and development	28,049	5,423
Operating loss	(34,093)	(10,010)
Other (expense) income:
Interest income	14	1
Interest expense	(288)	(12)
Other expense	(682)	(602)
Total other expense	(956)	(613)
Loss before income tax benefit	(35,049)	(10,623)
Income tax benefit	116	488
Net loss	(34,933)	(10,135)
Foreign currency translation adjustment	626	517
Comprehensive loss	$ (34,307)	$ (9,618)
Basic and diluted net loss per share (in dollars per share)	$ (67.91)	$ (34.64)
Weighted average shares outstanding - basic and diluted (in shares)	514,369	292,607

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Underwritten Public Offering [Member] Common Stock [Member]	Underwritten Public Offering [Member] Additional Paid-in Capital [Member]	Underwritten Public Offering [Member] Retained Earnings [Member]	Underwritten Public Offering [Member] AOCI Attributable to Parent [Member]	Underwritten Public Offering [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2020											241,495
Balances at Dec. 31, 2020											$ 0	$ 54,857	$ (46,026)	$ (384)	$ 8,447
Sale of common stock and warrants (in shares)	83,319
Sale of common stock and warrants	$ 0	$ 9,054	$ 0	$ 0	$ 9,054
Exercise of warrants for cash (in shares)											5,723				5,723
Exercise of warrants for cash											$ 0	1,042	0	0	$ 1,042
Exercise of warrants, cashless (in shares)											4,763
Exercise of warrants, cashless											$ 0	0	0	0	0
Vesting of restricted stock (in shares)											557
Vesting of restricted stock											$ 0	0	0	0	$ 0
Exercise of options, cashless (in shares)											104				197
Exercise of options, cashless											$ 0	0	0	0	$ 0
Stock-based compensation											0	1,287	0	0	1,287
Net loss											0	0	(10,135)	0	(10,135)
Foreign currency translation adjustment											$ 0	0	0	517	517
Balances (in shares) at Dec. 31, 2021											335,961
Balances at Dec. 31, 2021											$ 0	66,240	(56,161)	133	10,212
Sale of common stock and warrants (in shares)	502,500					28,345
Sale of common stock and warrants	$ 1	$ 5,302	$ 0	$ 0	$ 5,303	$ 0	$ 46	$ 0	$ 0	$ 46
Exercise of warrants for cash (in shares)											25
Exercise of warrants for cash											$ 0	5	0	0	$ 5
Vesting of restricted stock (in shares)											269
Exercise of options, cashless (in shares)											372				443
Exercise of options, cashless											$ 0	0	0	0	$ 0
Stock-based compensation											0	1,088	0	0	1,088
Net loss											0	0	(34,933)	0	(34,933)
Foreign currency translation adjustment											$ 0	0	0	626	626
Issuance of common stock, options and warrants - CPP acquistion (in shares)											182,988
Issuance of common stock, options and warrants - CPP acquistion											$ 0	9,605	0	0	9,605
Adjustment for fractional shares not issued, stock split (in shares)											(816)
Adjustment for fractional shares not issued, stock split											$ 0	(1)	0	0	(1)
Balances (in shares) at Dec. 31, 2022											1,049,644
Balances at Dec. 31, 2022											$ 1	$ 82,285	$ (91,094)	$ 759	$ (8,049)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (34,933)	$ (10,135)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,088	1,287
Non-cash interest expense	273	0
Changes in operating assets and liabilities:
Income tax receivable	212	51
Prepaid expenses and other current assets	(127)	247
Deposits held for clinical trial costs	(2,561)	(540)
Accounts payable	2,249	631
Accrued liabilities	786	1,214
Net cash used in operating activities	(15,276)	(7,245)
Cash flows from investing activities:
Cash acquired in merger	4	0
Net cash used in investing activities	(656)	0
Cash flows from financing activities:
Proceeds from exercise of warrants	5	1,042
Net cash provided by financing activities	5,354	10,096
Effect of exchange rate changes on cash	(4)	(6)
Net change in cash	(10,582)	2,845
Cash and cash equivalents at beginning of year	11,867	9,022
Cash and cash equivalents at end of year	1,285	11,867
Supplemental disclosure of cash flow information:
Cash paid during period for interest	15	12
Private Placement [Member]
Cash flows from financing activities:
Proceeds from sale of common stock,net of fees and offering costs	46
Underwritten Public Offering [Member]
Cash flows from financing activities:
Proceeds from sale of common stock,net of fees and offering costs	0	9,054
Proceeds from public offering of common stock and warrants net of underwriters discount and offering costs of $727	5,303
CPP [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Write off of in process research and development (IPR&D)	17,737	0
Cash flows from investing activities:
Investment in IPR&D	(660)	0
Supplemental disclosure of non-cash transactions:
Fair value of common stock, stock options and stock warrants issued as consideration for asset acquisition	$ 9,605	$ 0

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Private Placement [Member]
Proceeds from issuance of common stock and warrants, issuance costs	$ 44
Underwritten Public Offering [Member]
Proceeds from issuance of common stock and warrants, issuance costs	$ 727

Note 1 - Business

Note 1 - Business	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Panbela Therapeutics, Inc. (“Panbela”) and its direct wholly-owned subsidiaries: Cancer Prevention Pharmaceuticals, Inc. (“CPP”) and Panbela Research, Inc. (“Panbela Research”) and their respective subsidiaries, all of which are wholly owned exist for the primary purpose of developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. Panbela Therapeutics Pty Ltd is a wholly-owned subsidiary of Panbela Research organized under the laws of Australia. CPP has two The primary objective of our pipeline is the utilization of pharmacotherapies to reduce or normalize increased disease-associated polyamines using complementary pharmacotherapies. Our lead candidates are ivospemin (SBP- 101 1X Acquisition of CPP On June 15, 2022, February 21, 2022 ( 6, Reverse Stock Split Effective January 13, 2023, 1 9

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Nature of Operations [Text Block]	2. Risks and Uncertainties The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may We have incurred losses of $91.1 million since our inception in 2011. December 31, 2022, December 31, 2022 December 31, 2022, The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do not 101 1X 1X 3 December 2023 33 19” 19 2021, 19. no January 2022, not no

Note 3 - Liquidity and Manageme

Note 3 - Liquidity and Management Plans	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	3. Liquidity and Management Plans We will need to seek additional sources of funds to support our current business plans. We may no not If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions that may third Subsequent to December 31, 2022, 13 The company also sold shares of common stock via an At the Market (ATM) facility. During the quarter ended December 31, 2022, December 31, 2022 13 On October 4, 2022, December 31, 2022 Much of the development efforts under way regarding the asset acquired in the CPP acquisition are funded by a licensing partner, see Note 8, On July 2, 2021, first 2021, It is expected that our cash will last into the third 2023. Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for ivospemin (SBP- 101 1X 1X not not There can be no

Note 4 - Summary of Significant

Note 4 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	4. Summary of Significant Accounting Policies Basis of presentation We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on December 31. Principles of consolidation The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Panbela Therapeutics, Inc. and our direct and indirect subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Business Combinations and Asset Acquisition We account for acquired businesses using the acquisition method of accounting, which requires that the assets acquired, and liabilities assumed be recorded at the date of acquisition at their respective fair values if the acquisition meets the definition of a business combination. If the acquisition does not ASC 805, Concentration of credit risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits may December 31, 2022, not Cash and cash equivalents Cash equivalents include short-term, highly liquid investments with maturities of three Other noncurrent assets Other noncurrent assets are comprised primarily of long-term deposits with contract research organizations (“CROs”). These amounts are recognized as operating expenses or research and development expense as the trial is completed. Research and development costs Research and development costs include expenses incurred in the conduct of our human clinical trials, for third 101, 1X We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from CROs. Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as site openings, patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. Research and development costs also include IPR&D. This asset was acquired from the security holders of CPP and written off to research and development expense immediately subsequent to the asset acquisition. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no Clinical Trial Accruals Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors’ progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of the Company’s common stock. The assumed dividend yield is zero, as we do not The fair value of restricted stock units is calculated as the fair value of the underlying common stock as of the date of grant. Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not December 31, 2022 2021. Foreign currency translation The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended December 31, 2022 2021, The Company records transactions denominated in foreign currencies at the exchange rate in effect on that date. Fluctuations between the transaction date and settlement date are recognized as transaction gain/loss. Net loss per share We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive. The following outstanding potential common shares were not not December 31, 2022 2021 Employee and non-employee stock options 100,556 61,582 Restricted stock units - 269 Common stock issuable under common stock purchase warrants 889,910 127,710 990,466 189,561 Recently Adopted Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 December 15, 2021, December 31, 2022. not

Note 5 - Accrued Expenses

Note 5 - Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Accrued Liabilities [Text Block]	5. Accrued Expenses Accrued expenses consisted of the following (in thousands): December 31, 2022 2021 Clinical trial and related expenses $ 1,760 $ 992 Incentive compensation 550 434 Severance pay and related payroll taxes 448 - Professional services 147 235 Other 88 359 Total accrued liabilities $ 2,993 $ 2,020

Note 6 - Asset Acquisition

Note 6 - Asset Acquisition	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Asset Acquisition [Text Block]	6. Asset Acquisition On June 15, 2022, We performed the “screen test,” to determine if substantially all of the fair value of the gross assets acquired in the Mergers is concentrated in a single identifiable asset or group of similar identifiable assets. CPP’s lead asset, eflornithine in three 1X 1X 1X The contract consideration for the assets acquired includes certain contingent consideration which at the acquisition date is neither probable of occurring nor reasonably estimable. As such, the value of this contingent consideration has been excluded from the allocation of the purchase price below. Acquisition-related transaction costs incurred have been recorded as additional investment in IPR&D. The following is a summary of the purchase consideration and the allocation of that purchase consideration in connection with the CPP asset acquisition: Shares Value (in thousands) Common stock issued to CPP shareholders 182,978 $ 7,839 Common stock underlying options continued 39,904 1,637 Common stock underlying warrants replaced 8,452 129 Total non cash consideration $ 9,605 Transaction costs incurred $ 658 Total Consideration $ 10,263 In process research and development * $ 17,737 Cash 4 Other current assets 230 Accounts payable and accrued expenses (811 ) Accrued interest and notes payable (6,897 ) $ 10,263 * In accordance with FASB ASC Topic 730,

Note 7 - Notes Payable

Note 7 - Notes Payable	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Notes Payable Sucampo Promissory Note As of December 31, 2022, June 15, 2022. January 31,2023, January 31, 2024, January 31, 2025 January 31, 2026; January 31, 2027. January 31, 2023, January 31, 2023 October 4, 2022 November 4, 2022. not December 31, 2022, November 4, 2022. February 1, 2023 no December 31, 2022, June 15, 2022. Tillotts Promissory Note As of December 31, 2022, December 31, 2022 January 31, 2023.

Note 8 - License Agreement for

Note 8 - License Agreement for the Development and Commercialization of Flynpovi	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	8. License Agreement for the Development and Commercialization of Flynpovi CPP is party to a license agreement with One-Two Therapeutics Assets Limited (“One-Two”) dated as of July 16, 2021. not

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies License agreement with the University of Florida Research Foundation On December 22, 2011, December 12, 2016 ( October 3, 2019 ( 1 ten first 2 The amended license agreement remains subject to customary and usual termination provisions. The Company must also pay an annual license maintenance fee of $10,000. License Agreement with the University of Arizona CPP is party to a license agreement with the Arizona Board of Regents of the University of Arizona (the “University”). Pursuant to an Inter-institutional Agreement, the Regents of the University of California on behalf of the University of California, Irvine, has agreed to license certain patents, provisional patents, clinical trial data and other intellectual property related to the chemoprevention of cancer, the prevention of polyps and other technologies to CPP. The University has the right to administer the joint patent rights held between the University and the University of California, Irvine. The license agreement gives CPP exclusive rights to commercialize products based on intellectual property. In exchange for the intellectual property, CPP paid the University certain fees and reimbursements of patent costs and granted the university a warrant to acquire shares of CPP. As a result of the Mergers, the warrant was replaced with a warrant to purchase 2,772 shares of common stock of Panbela at a price of $11.20 per share. CPP also agreed to pay the University additional milestone payments totaling up to $90,000 upon the achievement of certain research, development and regulatory milestones. Future milestone payments are considered to be contingent consideration and will be accrued when probable of being paid. As of December 31, 2022, no

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders Equity Public offering of common stock and warrants On October 4, 2022, December 31, 2022. 1. At-the-Market Program On July 19, 2022, During the last month of the year ended December 31, 2022, December 2022 December 31, 2022 Public offering of common stock On July 2, 2021, 3. Exercise of Warrants to purchase common stock During the year ended December 31, 2021 During the year ended December 31, 2021, 1. During the same period, the Company issued an additional 4,762 shares of common stock resulting from the net, cashless, exercise of outstanding warrants to purchase 13,403 shares. Warrants to purchase a total of 14,333 shares of common stock, all having an exercise price of $5.00 per share, expired during the year ended December 31, 2021. December 31, 2021. Reverse Stock Split On November 29, 2022, one forty 1:40 January 13, 2023, forty one 1 No not January 13, 2023, one forty 1:40 January 13, 2023. January 13, 2023. Shares reserved Shares of common stock reserved for future issuance were as follows as of December 31, 2022: Stock options outstanding 100,556 Shares available for grant under equity incentive plan 50,511 Common shares issuable under outstanding common stock purchase warrants 889,910 1,040,977

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	11. Stock-Based Compensation 2016 The 2016 April 9, 2020 ( “2016 2016 2016 no 2016 ten 2016 December 31, 2022, 2016 2011 Prior to approval of the 2016 2011 “2011 2016 2011 2011 2011 ten zero two December 31, 2022, 2011 CPP s 2010 As a result of the Mergers, the Company has assumed all remaining rights and obligations with respect to CPP’s 2010 December 31, 2022, We recognize stock-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest. A summary of option activity is as follows: Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2021 53,438 $ 270.92 $ 388,461 Granted 13,851 154.55 Exercised (197 ) 35.20 Cancelled - - Forfeitures (5,510 ) 410.75 Balance at December 31, 2021 61,582 $ 233.00 $ 8,821 Options continued from CPP plan 39,904 14.00 Exercised (443 ) 8.80 Cancelled - - Forfeitures (487 ) 562.97 Balance at December 31, 2022 100,556 $ 145.50 $ - Stock-based compensation expense for each of the periods presented is as follows (in thousands): Year ended December 31, 2022 2021 General and administative $ 889 $ 1,083 Research and development 199 204 Total stock based compensation $ 1,088 $ 1,287 A summary of the status of our unvested shares during the two December 31, 2022 Shares Under Option Weighted Average Grant Date Fair Value Unvested at January 1, 2021 12,653 $ 166.80 Granted 13,851 118.93 Vested (7,153 ) 144.41 Forfeitures (1,250 ) 119 Unvested at December 31, 2021 18,101 $ 137.41 Granted - - Vested (8,184 ) 135.03 Forfeitures (487 ) 562.93 Unvested at December 31, 2022 9,430 $ 139.04 Information about stock options outstanding, vested and expected to vest as of December 31, 2022, Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $8.80 - $58.80 39,810 7.12 $ 14.31 39,810 7.12 $90.40 - $91 1,578 8.02 $ 90.46 625 6.99 $100 - 166.80 30,595 6.38 $ 135.94 24,383 5.90 $180 - $244 11,676 5.94 $ 208.29 10,738 5.81 $324 - $404 12,051 6.19 $ 365.14 10,724 6.02 $604 4,846 3.95 $ 604.00 4,846 3.95 Totals 100,556 6.62 $ 145.50 91,126 6.34 As of December 31, 2022, not No new options were granted during the year ended December 31, 2022. June 15, 2022, Non-employee stock-based compensation We account for stock options granted to nonemployees in accordance with Accounting Standards Update (“ASU”) 2019 07, 718 2022 2021, Restricted stock units The number and weighted average grant date fair value of restricted non vested common stock for the most recent completed fiscal years is as follows: Number of Restricted Shares Weighted Average Grant Date Fair Value Restricted nonvested at January 1, 2021 287 $ 138.00 Granted in 2021 539 166.80 Vested in 2021 (557 ) 152.00 Restricted nonvested at December 31, 2021 269 $ 138.00 Granted in 2022 - - Vested in 2022 (269 ) 67.60 Restricted nonvested at December 31, 2022 - $ - As of December 31, 2022, no Stock compensation expense includes expense related to restricted stock units of approximately $43,000 and $106,000 during the years ended December 31,2022 December 31, 2021,

Note 12 - Income Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. Income Taxes We have incurred net operating losses since our inception. We have not On December 31, 2022 2021, Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as operating losses and tax credit carryforwards. The significant components of our deferred tax assets and liabilities are as follows (in thousands): 2022 Tax Expense: Current (116 ) Deferred - Noncurrent - (116 ) December 31, Deferred tax assets (liabilities) 2022 2021 Net operating loss carryforwards $ 17,564 $ 9,986 Research credit carryforwards 338 235 Stock-based compensation 1,928 1,734 Section 174 amortization 1,921 - Other 68 66 Deferred tax assets 21,819 12,021 Valuation allowance (21,819 ) (12,021 ) Net deferred tax asset $ - $ - Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry-forward period. Because of our history of operating losses, management believes that the deferred tax assets arising from the above-mentioned future tax benefits are currently not A reconciliation of the statutory tax rates and the effective tax rates is as follows: Year Ended December 31, 2022 2021 Statutory rate 21.0 % 21.0 % Permanent differences (10.8 ) 2.1 Change in effective tax rate 0.0 (0.4 ) States 0.1 - Valuation allowance (13.0 ) (24.3 ) Foreign research incentives 0.1 3.1 Other 2.9 1.6 Effective rate 0.3 % 3.1 % Net operating losses and tax credit carryforwards as of December 31, 2022, (In Thousands) Amount Expiration Years Net operating losses--federal 23,068 Expires beginning 2031 2018 to 2022 net operating losses -- federal 23,977 Never expires Tax credits--federal 338 Beginning 2041 Utilization of the net operating loss carryforwards and credits may not 382 The Company is subject to taxation in the United States and Australia. Tax returns for the year ended December 31, 2017 December 31, 2015

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Events During the month of January 2023, On January 30, 2023, February 2, 2023. 1.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on December 31.
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Panbela Therapeutics, Inc. and our direct and indirect subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Business Combinations Policy [Policy Text Block]	Business Combinations and Asset Acquisition We account for acquired businesses using the acquisition method of accounting, which requires that the assets acquired, and liabilities assumed be recorded at the date of acquisition at their respective fair values if the acquisition meets the definition of a business combination. If the acquisition does not ASC 805,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits may December 31, 2022, not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents Cash equivalents include short-term, highly liquid investments with maturities of three
Other Non-current Assets [Policy Text Block]	Other noncurrent assets Other noncurrent assets are comprised primarily of long-term deposits with contract research organizations (“CROs”). These amounts are recognized as operating expenses or research and development expense as the trial is completed.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs include expenses incurred in the conduct of our human clinical trials, for third 101, 1X We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from CROs. Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as site openings, patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. Research and development costs also include IPR&D. This asset was acquired from the security holders of CPP and written off to research and development expense immediately subsequent to the asset acquisition. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no
Clinical Trial Accruals [Policy Text Block]	Clinical Trial Accruals Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors’ progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may
Share-Based Payment Arrangement [Policy Text Block]	Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of the Company’s common stock. The assumed dividend yield is zero, as we do not The fair value of restricted stock units is calculated as the fair value of the underlying common stock as of the date of grant.
Income Tax, Policy [Policy Text Block]	Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not December 31, 2022 2021.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended December 31, 2022 2021, The Company records transactions denominated in foreign currencies at the exchange rate in effect on that date. Fluctuations between the transaction date and settlement date are recognized as transaction gain/loss.
Earnings Per Share, Policy [Policy Text Block]	Net loss per share We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive. The following outstanding potential common shares were not not December 31, 2022 2021 Employee and non-employee stock options 100,556 61,582 Restricted stock units - 269 Common stock issuable under common stock purchase warrants 889,910 127,710 990,466 189,561
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 December 15, 2021, December 31, 2022. not

Note 4 - Summary of Significa_2

Note 4 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2022 2021 Employee and non-employee stock options 100,556 61,582 Restricted stock units - 269 Common stock issuable under common stock purchase warrants 889,910 127,710 990,466 189,561

Note 5 - Accrued Expenses (Tabl

Note 5 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2022 2021 Clinical trial and related expenses $ 1,760 $ 992 Incentive compensation 550 434 Severance pay and related payroll taxes 448 - Professional services 147 235 Other 88 359 Total accrued liabilities $ 2,993 $ 2,020

Note 6 - Asset Acquisition (Tab

Note 6 - Asset Acquisition (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Asset Acquisition [Table Text Block]	Shares Value (in thousands) Common stock issued to CPP shareholders 182,978 $ 7,839 Common stock underlying options continued 39,904 1,637 Common stock underlying warrants replaced 8,452 129 Total non cash consideration $ 9,605 Transaction costs incurred $ 658 Total Consideration $ 10,263 In process research and development * $ 17,737 Cash 4 Other current assets 230 Accounts payable and accrued expenses (811 ) Accrued interest and notes payable (6,897 ) $ 10,263

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	Shares of common stock reserved for future issuance were as follows as of December 31, 2022: Stock options outstanding 100,556 Shares available for grant under equity incentive plan 50,511 Common shares issuable under outstanding common stock purchase warrants 889,910 1,040,977

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2021 53,438 $ 270.92 $ 388,461 Granted 13,851 154.55 Exercised (197 ) 35.20 Cancelled - - Forfeitures (5,510 ) 410.75 Balance at December 31, 2021 61,582 $ 233.00 $ 8,821 Options continued from CPP plan 39,904 14.00 Exercised (443 ) 8.80 Cancelled - - Forfeitures (487 ) 562.97 Balance at December 31, 2022 100,556 $ 145.50 $ -
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year ended December 31, 2022 2021 General and administative $ 889 $ 1,083 Research and development 199 204 Total stock based compensation $ 1,088 $ 1,287
Schedule of Nonvested Share Activity [Table Text Block]	Shares Under Option Weighted Average Grant Date Fair Value Unvested at January 1, 2021 12,653 $ 166.80 Granted 13,851 118.93 Vested (7,153 ) 144.41 Forfeitures (1,250 ) 119 Unvested at December 31, 2021 18,101 $ 137.41 Granted - - Vested (8,184 ) 135.03 Forfeitures (487 ) 562.93 Unvested at December 31, 2022 9,430 $ 139.04
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $8.80 - $58.80 39,810 7.12 $ 14.31 39,810 7.12 $90.40 - $91 1,578 8.02 $ 90.46 625 6.99 $100 - 166.80 30,595 6.38 $ 135.94 24,383 5.90 $180 - $244 11,676 5.94 $ 208.29 10,738 5.81 $324 - $404 12,051 6.19 $ 365.14 10,724 6.02 $604 4,846 3.95 $ 604.00 4,846 3.95 Totals 100,556 6.62 $ 145.50 91,126 6.34
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Restricted Shares Weighted Average Grant Date Fair Value Restricted nonvested at January 1, 2021 287 $ 138.00 Granted in 2021 539 166.80 Vested in 2021 (557 ) 152.00 Restricted nonvested at December 31, 2021 269 $ 138.00 Granted in 2022 - - Vested in 2022 (269 ) 67.60 Restricted nonvested at December 31, 2022 - $ -

Note 12 - Income Taxes (Tables)

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2022 Tax Expense: Current (116 ) Deferred - Noncurrent - (116 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, Deferred tax assets (liabilities) 2022 2021 Net operating loss carryforwards $ 17,564 $ 9,986 Research credit carryforwards 338 235 Stock-based compensation 1,928 1,734 Section 174 amortization 1,921 - Other 68 66 Deferred tax assets 21,819 12,021 Valuation allowance (21,819 ) (12,021 ) Net deferred tax asset $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2022 2021 Statutory rate 21.0 % 21.0 % Permanent differences (10.8 ) 2.1 Change in effective tax rate 0.0 (0.4 ) States 0.1 - Valuation allowance (13.0 ) (24.3 ) Foreign research incentives 0.1 3.1 Other 2.9 1.6 Effective rate 0.3 % 3.1 %
Summary of Operating Loss and Tax Credit Carryforwards [Table Text Block]	(In Thousands) Amount Expiration Years Net operating losses--federal 23,068 Expires beginning 2031 2018 to 2022 net operating losses -- federal 23,977 Never expires Tax credits--federal 338 Beginning 2041

Note 1 - Business (Details Text

Note 1 - Business (Details Textual) - Reverse Stock Split [Member]	Jan. 13, 2023	Nov. 29, 2022
Stockholders' Equity Note, Stock Split, Conversion Ratio		40
Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	40

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Retained Earnings (Accumulated Deficit), Total	$ (91,094)	$ (56,161)
Net Income (Loss) Attributable to Parent, Total	(34,933)	(10,135)
Net Cash Provided by (Used in) Operating Activities, Total	(15,276)	(7,245)
Cash and Cash Equivalents, at Carrying Value, Total	1,285	11,867
Working Capital	(6,000)
Stockholders' Equity Attributable to Parent, Ending Balance	(8,049)	$ 10,212	$ 8,447
CPP Asset Acquisition [Member]
Research and Development in Process	$ 17,700

Note 3 - Liquidity and Manage_2

Note 3 - Liquidity and Management Plans (Details Textual) - USD ($)				1 Months Ended		2 Months Ended	3 Months Ended		12 Months Ended
	Jan. 30, 2023	Oct. 04, 2022	Jul. 02, 2021	Jan. 31, 2023	Jan. 30, 2023	Mar. 23, 2021	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Proceeds from Warrant Exercises						$ 1,000,000			$ 5,000	$ 1,042,000
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)						5,598				5,723
Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		325,325
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.001
Proceeds from Warrant Exercises							$ 13,000
Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		753,749
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 12
Subsequent Event [Member] | Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,832,776				1,832,776
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.001				$ 0.001
Subsequent Event [Member] | Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	13,350,000				13,350,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.75				$ 2.75
Registered Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total		$ 5,300,000
Stock Issued During Period, Shares, New Issues (in shares)		177,175
Proceeds from Issuance of Common Stock		$ 6,000,000
Units Issued, Stock and Warrant, Price Per Share (in dollars per share)		$ 12
Units Issued, Stock and Warrant, Number of Warrants Per Unit (in shares)		1.5
Units Issued, Warrant and Warrant, Price Per Unit (in dollars per share)		$ 11.999
Units Issued, Warrant and Warrant, Warrant Per Unit (in shares)		1.5
Registered Public Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 15,000,000
Stock Issued During Period, Shares, New Issues (in shares)	4,842,224
Units Issued, Stock and Warrant, Price Per Share (in dollars per share)	$ 2.25				$ 2.25
Units Issued, Stock and Warrant, Number of Warrants Per Unit (in shares)	2				2
Units Issued, Warrant and Warrant, Price Per Unit (in dollars per share)	$ 2.249				$ 2.249
Units Issued, Warrant and Warrant, Warrant Per Unit (in shares)	2				2
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)								28,343	28,343
Proceeds from Issuance of Common Stock								$ 93,000	$ 93,000
Proceeds from Issuance of Common Stock, Net									46,000
ATM Program [Member] | Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity, Total				$ 1,600,000
Stock Issued During Period, Shares, New Issues (in shares)				440,830
Proceeds from Issuance of Common Stock					$ 1,600,000
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			83,333
Proceeds from Issuance of Common Stock			$ 10,000,000
Shares Issued, Price Per Share (in dollars per share)			$ 120
Proceeds from Issuance of Common Stock, Net			$ 9,100,000						$ 0	$ 9,054,000

Note 4 - Summary of Significa_3

Note 4 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	Dec. 31, 2022 USD ($)
Cash, Uninsured Amount	$ 1

Note 4 - Summary of Significa_4

Note 4 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Anti-dilutive securities (in shares)	990,466	189,561
Share-Based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	100,556	61,582
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)	0	269
Warrant [Member]
Anti-dilutive securities (in shares)	889,910	127,710

Note 5 - Accrued Expenses - Acc

Note 5 - Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Clinical trial and related expenses	$ 1,760	$ 992
Incentive compensation	550	434
Severance pay and related payroll taxes	448	0
Professional services	147	235
Other	88	359
Accrued liabilities	$ 2,993	$ 2,020

Note 6 - Asset Acquisition (Det

Note 6 - Asset Acquisition (Details Textual) $ in Millions	Jun. 15, 2022 USD ($)
Maximum [Member] | CPP Asset Acquisition [Member]
Asset Acquisition, Contingent Consideration, Liability, Total	$ 60

Note 6 - Asset Acquisition - Su

Note 6 - Asset Acquisition - Summary of the Purchase Consideration and the Allocation of That Purchase Consideration (Details) - USD ($) $ in Thousands			12 Months Ended
		Jun. 15, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash			$ 4	$ 0
CPP Asset Acquisition [Member]
Common stock issued to CPP shareholders (in shares)		182,978
Value of Consideration Given		$ 9,605
Common stock underlying options continued (in shares)		39,904
Common stock underlying warrants replaced (in shares)		8,452
Transaction costs incurred		$ 658
Total Consideration		10,263
In process research and development *	[1]	17,737
Cash		4
Other current assets		230
Accounts payable and accrued expenses		(811)
Accrued interest and notes payable		(6,897)
Asset Acquisition, Assets Acquired		10,263
CPP Asset Acquisition [Member] | Common Stock Issued as Consideration [Member]
Value of Consideration Given		7,839
CPP Asset Acquisition [Member] | Options Issued as Consideration [Member]
Value of Consideration Given		1,637
CPP Asset Acquisition [Member] | Warrants Issued as Consideration [Member]
Value of Consideration Given		$ 129
[1]In accordance with FASB ASC Topic 730 this asset was immediately expensed upon the closing of the merger

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Feb. 01, 2023	Oct. 04, 2022	Jun. 15, 2022	Dec. 31, 2022	Nov. 04, 2022
Registered Public Offering [Member]
Proceeds from Issuance of Common Stock		$ 6,000,000
Sucampo Note [Member]
Long-Term Debt, Total			$ 6,200,000	$ 6,400,000
Debt Instrument, Interest Rate, Stated Percentage			5%
Debt Instrument, Periodic Payment, Total			$ 1,000,000
Debt Instrument, Covenant, Equity Raise, Maximum Amount to Pay			$ 1,000,000
Debt Instrument, Covenant, Equity Raise, Percentage of Cash Proceeds		10%	10%
Debt Instrument, Equity Raise, Amount Owed					$ 600,000
Debt Instrument, Penalty Interest, Percent					5%
Interest Payable				243,000
Sucampo Note [Member] | Subsequent Event [Member]
Repayments of Long-Term Debt, Total	$ 1,000,000
Interest Payable	$ 295,000
Tillotts Note [Member]
Long-Term Debt, Total				$ 700,000
Debt Instrument, Interest Rate, Stated Percentage				4%
Interest Payable				$ 82,000
Debt Instrument, Face Amount				$ 650,000

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual) - USD ($)	Dec. 22, 2011	Dec. 31, 2022
License Agreement, Milestone Payments Achievement		$ 90,000
University Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,772
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 11.20
Licensing Agreement with University of Florida Research Foundation [Member]
Royalty Term (Year)	10 years
Annual License Maintenance Fee	$ 10,000
Licensing Agreement with University of Florida Research Foundation [Member] | Minimum [Member]
Royalty Fee Percentage of Net Sales	2.50%
Licensing Agreement with University of Florida Research Foundation [Member] | Maximum [Member]
Royalty Fee Percentage of Net Sales	5%

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual)				2 Months Ended	3 Months Ended		12 Months Ended
	Nov. 29, 2022	Oct. 04, 2022 USD ($) $ / shares shares	Jul. 02, 2021 USD ($) $ / shares shares	Mar. 23, 2021 USD ($) shares	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) $ / shares shares	Jul. 19, 2022 USD ($)
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)				5,598				5,723
Proceeds from Warrant Exercises | $				$ 1,000,000			$ 5,000	$ 1,042,000
Stock Issued During Period, Shares, Warrants Exercised (in shares)								4,762
Stock Issued During Period, Shares, Exercise of Warrants on Cashless Basis (in shares)								13,403
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	40
Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		325,325
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.001
Proceeds from Warrant Exercises | $					$ 13,000
Warrants With Exercise Price of $181.60 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 181.60
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)								25
Proceeds from Warrant Exercises | $								$ 4,500
Exercise of Warrants To Purchase Common Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 181.60
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)								5,598
Warrants With Exercise Price of $5.00 [Member]
Class of Warrants or Rights, Cancelled During the Period (in shares)								14,333
Class of Warrant or Right, Cancelled During Period, Exercise Price (in dollars per share) | $ / shares								$ 5
Warrants With Exercise Price of $15.00 [Member]
Class of Warrants or Rights, Cancelled During the Period (in shares)								2,714
Class of Warrant or Right, Cancelled During Period, Exercise Price (in dollars per share) | $ / shares								$ 15
Registered Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		177,175
Units Issued, Stock and Warrant, Price Per Share (in dollars per share) | $ / shares		$ 12
Units Issued, Stock and Warrant, Number of Warrants Per Unit (in shares)		1.5
Units Issued, Warrant and Warrant, Price Per Unit (in dollars per share) | $ / shares		$ 11.999
Units Issued, Warrant and Warrant, Warrant Per Unit (in shares)		1.5
Proceeds from Issuance or Sale of Equity, Total | $		$ 5,300,000
Proceeds from Issuance of Common Stock | $		$ 6,000,000
Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		753,749
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 12
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)						28,343	28,343
Equity Offering, Maximum Amount | $									$ 8,400,000
Proceeds from Issuance of Common Stock | $						$ 93,000	$ 93,000
Payments of Stock Issuance Costs | $							$ 44,000
Equity Offering, Commission, Percentage of Gross Proceeds							3%
Proceeds from Issuance of Common Stock, Net | $							$ 46,000
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			83,333
Proceeds from Issuance of Common Stock | $			$ 10,000,000
Payments of Stock Issuance Costs | $							727,000	$ 946,000
Proceeds from Issuance of Common Stock, Net | $			$ 9,100,000				$ 0	$ 9,054,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 120

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)	Dec. 31, 2022 shares
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	1,040,977
Warrant [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	889,910
Share-Based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	100,556
Shares Available for Grant Under Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	50,511

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jun. 15, 2022	Dec. 31, 2020
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	1,040,977
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 145.50
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	100,556	61,582		53,438
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	0	13,851
Share-Based Payment Arrangement, Expense	$ 1,088,000	$ 1,287,000
Share-Based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	100,556
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 800,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 1 month 6 days
Non-Employee Stock Option [Member]
Share-Based Payment Arrangement, Expense	$ 281,000	222,000
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expense	$ 43,000	$ 106,000
Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	106,825
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	55,495
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 241.65
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	6 years 6 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	50,511
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	5,600
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 118.92
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	2 years
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	0 years
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years
CPP's 2010 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	39,461
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 14.013
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	7 years 2 months 12 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)			39,904
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)			$ 14

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Balance, shares available for grant (in shares)	61,582	53,438
Balance, weighted average exercise price per share (in dollars per share)	$ 233	$ 270.92
Aggregate intrinsic value	$ 0	$ 8,821	$ 388,461
Granted, shares available for grant (in shares)	39,904	13,851
Granted, weighted average exercise price per share (in dollars per share)	$ 14	$ 154.55
Excercised, shares available for grant (in shares)	(443)	(197)
Excercised, weighted average exercise price per share (in dollars per share)	$ 8.80	$ 35.20
Cancelled, shares available for grant (in shares)	0	0
Cancelled, weighted average exercise price per share (in dollars per share)	$ 0	$ 0
Forfeitures , shares available for grant (in shares)	(487)	(5,510)
Forfeitures, weighted average exercise price per share (in dollars per share)	$ 562.97	$ 410.75
Balance, shares available for grant (in shares)	100,556	61,582
Balance, weighted average exercise price per share (in dollars per share)	$ 145.50	$ 233

Note 11 - Stock-based Compens_5

Note 11 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based compensation expense	$ 1,088	$ 1,287
General and Administrative Expense [Member]
Share-based compensation expense	889	1,083
Research and Development Expense [Member]
Share-based compensation expense	$ 199	$ 204

Note 11 - Stock-based Compens_6

Note 11 - Stock-based Compensation - Nonvested Share Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Unvested, shares under option (in shares)	18,101	12,653
Unvested, weighted average grant-date fair value (in dollars per share)	$ 137.41	$ 166.80
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	0	13,851
Granted, weighted average grant-date fair value (in dollars per share)	$ 0	$ 118.93
Vested, shares under option (in shares)	(8,184)	(7,153)
Vested, weighted average grant-date fair value (in dollars per share)	$ 135.03	$ 144.41
Forfeitures (in shares)	(487)	(1,250)
Forfeitures (in dollars per share)	$ 562.93	$ 119
Unvested, shares under option (in shares)	9,430	18,101
Unvested, weighted average grant-date fair value (in dollars per share)	$ 139.04	$ 137.41

Note 11 - Stock-based Compens_7

Note 11 - Stock-based Compensation - Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Options outstanding (in shares) | shares	100,556
Options outstanding, weighted average remaining contractual life (Year)	6 years 7 months 13 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 145.50
Options exercisable (in shares) | shares	91,126
Options excercisable, weighted average remaining contractual life (Year)	6 years 4 months 2 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 8.80
Per share exercise price, upper limit (in dollars per share)	$ 58.80
Options outstanding (in shares) | shares	39,810
Options outstanding, weighted average remaining contractual life (Year)	7 years 1 month 13 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 14.31
Options exercisable (in shares) | shares	39,810
Options excercisable, weighted average remaining contractual life (Year)	7 years 1 month 13 days
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 90.40
Per share exercise price, upper limit (in dollars per share)	$ 91
Options outstanding (in shares) | shares	1,578
Options outstanding, weighted average remaining contractual life (Year)	8 years 7 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 90.46
Options exercisable (in shares) | shares	625
Options excercisable, weighted average remaining contractual life (Year)	6 years 11 months 26 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 100
Per share exercise price, upper limit (in dollars per share)	$ 166.80
Options outstanding (in shares) | shares	30,595
Options outstanding, weighted average remaining contractual life (Year)	6 years 4 months 17 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 135.94
Options exercisable (in shares) | shares	24,383
Options excercisable, weighted average remaining contractual life (Year)	5 years 10 months 24 days
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 180
Per share exercise price, upper limit (in dollars per share)	$ 244
Options outstanding (in shares) | shares	11,676
Options outstanding, weighted average remaining contractual life (Year)	5 years 11 months 8 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 208.29
Options exercisable (in shares) | shares	10,738
Options excercisable, weighted average remaining contractual life (Year)	5 years 9 months 21 days
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 324
Per share exercise price, upper limit (in dollars per share)	$ 404
Options outstanding (in shares) | shares	12,051
Options outstanding, weighted average remaining contractual life (Year)	6 years 2 months 8 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 365.14
Options exercisable (in shares) | shares	10,724
Options excercisable, weighted average remaining contractual life (Year)	6 years 7 days
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 604
Options outstanding (in shares) | shares	4,846
Options outstanding, weighted average remaining contractual life (Year)	3 years 11 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 604
Options exercisable (in shares) | shares	4,846
Options excercisable, weighted average remaining contractual life (Year)	3 years 11 months 12 days

Note 11 - Stock-based Compens_8

Note 11 - Stock-based Compensation - Nonvested Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Restricted nonvested (in shares)	269	287
Restricted nonvested, weighted average grant date fair value (in dollars per share)	$ 138	$ 138
Granted, restricted shares (in shares)	0	539
Granted, weighted average grant date fair value (in dollars per share)	$ 0	$ 166.80
Vested, restricted shares (in shares)	(269)	(557)
Vested, weighted average grant date fair value (in dollars per share)	$ 67.60	$ 152
Restricted nonvested (in shares)	0	269
Restricted nonvested, weighted average grant date fair value (in dollars per share)	$ 0	$ 138

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes Receivable, Current	$ 49,000	$ 321,000
Domestic Tax Authority [Member]
Open Tax Year	2015 2016 2017 2018 2019 2020 2021 2022

Note 12 - Income Taxes - Compon

Note 12 - Income Taxes - Components of Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current	$ (116)
Deferred	0
Noncurrent	0
Income Tax Expense (Benefit), Total	$ (116)	$ (488)

Note 12 - Income Taxes - Deferr

Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Net operating loss carryforwards	$ 17,564	$ 9,986
Research credit carryforwards	338	235
Stock-based compensation	1,928	1,734
Section 174 amortization	1,921	0
Other	68	66
Deferred tax assets	21,819	12,021
Valuation allowance	(21,819)	(12,021)
Net deferred tax asset	$ 0	$ 0

Note 12 - Income Taxes - Income

Note 12 - Income Taxes - Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statutory rate	21%	21%
Permanent differences	(10.80%)	2.10%
Change in effective tax rate	0%	(0.40%)
States	0.10%	0%
Valuation allowance	(13.00%)	(24.30%)
Foreign research incentives	0.10%	3.10%
Other	2.90%	1.60%
Effective rate	0.30%	3.10%

Note 12 - Income Taxes - Net Op

Note 12 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details) - Domestic Tax Authority [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Net operating losses--federal	$ 23,068
Tax credits--federal	$ 338
Earliest Tax Year [Member]
Net operating losses--federal	2031
Tax credits--federal	2041
Tax Year 2018 [Member]
Net operating losses--federal	$ 23,977

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 30, 2023	Oct. 04, 2022	Jan. 31, 2023	Dec. 31, 2022	Dec. 31, 2022
Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		325,325
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.001
Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		753,749
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 12
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)				28,343	28,343
Registered Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		177,175
Proceeds from Issuance or Sale of Equity, Total		$ 5.3
Units Issued, Stock and Warrant, Price Per Share (in dollars per share)		$ 12
Units Issued, Stock and Warrant, Number of Warrants Per Unit (in shares)		1.5
Units Issued, Warrant and Warrant, Price Per Unit (in dollars per share)		$ 11.999
Units Issued, Warrant and Warrant, Warrant Per Unit (in shares)		1.5
Subsequent Event [Member] | Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,832,776
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.001
Subsequent Event [Member] | Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	13,350,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.75
Subsequent Event [Member] | ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)			440,830
Proceeds from Issuance or Sale of Equity, Total			$ 1.6
Subsequent Event [Member] | Registered Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	4,842,224
Proceeds from Issuance or Sale of Equity, Total	$ 15
Units Issued, Stock and Warrant, Price Per Share (in dollars per share)	$ 2.25
Units Issued, Stock and Warrant, Number of Warrants Per Unit (in shares)	2
Units Issued, Warrant and Warrant, Price Per Unit (in dollars per share)	$ 2.249
Units Issued, Warrant and Warrant, Warrant Per Unit (in shares)	2
Proceeds from Issuance or Sale of Equity, Net	$ 13.7